Nrf2 as a Target for Intervening Pulmonary and Systemic Inflammation

Sustained inflammation is critical in the development of several pathophysiological diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma, sepsis, acute lung injury, cardiovascular disease, in addition to cancer. Research suggests that controlling inflammation is an effective mechanism for intervention but the current inflammation reducers, such as cox-2 inhibitors, are being proscribed due to negative long term side-effects. Researchers at JHU have discovered a novel gene target, Nrf2, that is involved in the protection against inflammation in preclinical mouse models of COPD, asthma, and sepsis. Description (Set) Proposed Use (Set) The marketplace for a drug controlling inflammation for the treatment of COPD and asthma alone would be vast. It has been estimated that 4-10% of the world population suffers from COPD, and approximately 100 million suffer from chronic asthma. This invention is poised to make a major impact in the treatment of all diseases where inflammation plays an important role in pathophysiology.

Inventor(s): Biswal, Shyam

Type of Offer: Licensing



Next Patent »
« More Pharmaceutical Patents

Share on      


CrowdSell Your Patent